Type 2 Diabetes

Are you Overweight and have Type 2 Diabetes?

Lakeland Clinical Trials is conducting a clinical trial to investigate an oral medication.

You may be eligible to participate if:

  • You are aged 18-65 years
  • Able to participate for up to 17 weeks
  • Treated with Metformin only for your diabetes
  • Overweight: BMI >30 kg/m²

The study will compare the active study drug to placebo (a 'dummy' medication).

One person in four will receive the placebo and three people in four will receive active study drug. This will be decided randomly and participants will not know which of these they receive during the study.

For more information contact us on 07 3477870 or apply below.

Project Data

SPONSOR

Scohia Pharma, Inc.

Apply to Participate

Seeking volunteers with Type 2 Diabetes for the SCORED Trial

Participants must also have cardiovascular risk factors and moderately impaired kidney function.

What is the purpose of the SCORED Trial?

The SCORED Trial is a phase III clinical trial designed to show if the study drug does not increase the risk of having a cardiovascular event, such as heart attack or stroke, in patients with Type 2 Diabetes and kidney disease.

The trial will also study if the study drug can instead decrease the risk of these events. Eligible patients must also have cardiovascular risk factors and moderately impaired kidney function. Patients will be randomly selected to receive the study drug or placebo, which is a tablet that looks like the study drug, but does not contain the active drug ingredient.

  • Am I eligible to participate?
  • You may be eligible if you:
  • Have Type 2 Diabetes
  • Have impaired kidney function
  • Are 18+ years old with at least one major cardiovascular risk
  • Are 55+ years old with at least two minor cardiovascular risks

Additional requirements will be discussed with a study representative. Qualified patients will receive study-related care at no cost.

What will I be required to do to join the trial?

Participation in the SCORED Trial consists of three periods:

SCREENING - to determine eligibility to participate

TREATMENT - receive either the study drug or placebo

FOLLOW-UP - final procedures/assessments

How long will participation last?

The duration of treatment (investigational drug or placebo) will be approximately 27-51 months and will include a follow-up time period. There will be 6 on-site visits within the first six months and then one on-site visit every 26 weeks until the completion of the study.

Project Data
SPONSOR
Sanofi

Apply to Participate

Subscribe to RSS - Type 2 Diabetes